$CNAT News and may explain WHY Roth Capital initiated a "BUY" rating and $20 price target- maybe they know something seeing as how THEY are moderating the conference call and the Q&A.
"SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) will host a conference call and webcast presentation at 12:00 p.m. ET on Tuesday, February 20, with liver disease expert Paul Pockros, M.D., director of the Liver Disease Center at Scripps Clinic in La Jolla, CA. Dr. Pockros will address the unmet medical need in hepatitis C virus (HCV) infected patients who have achieved a sustained viral response (SVR) through treatment with antiviral drugs, but who still suffer from residual liver fibrosis or cirrhosis. Conatus President, Chief Executive Officer and co-founder, Steven J. Mento, Ph.D., will discuss the design and potential outcomes of the company’s ongoing Phase 2b clinical trial in post orthotopic liver transplant (POLT) HCV-SVR patients, for which top-line results are expected in the second quarter of 2018. Roth Capital Partners managing director and biotechnology research analyst Yasmeen Rahimi, Ph.D., will moderate the call and lead the Q&A session.
“While the new direct-acting antiviral drugs have provided tremendous benefit for HCV patients, we believe those achieving SVR after development of advanced fibrosis or cirrhosis may be cleared of the virus, but still not cured of the underlying liver damage,” said Dr. Mento. “As we approach the completion of the POLT-HCV-SVR trial, we want to remind people of the patient population, the trial design and endpoints, and the potential paths forward in related populations depending on results.”
News 
Market Data 
Discover 
